Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 4,271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ADM Clear all

Conditions: Concussion, Mild
Interventions: Behavioral Control, Targeted Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 99 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: Motivational group sessions, Time and attention control group sessions; Behavioral · Other
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 22 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin; Drug · Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 50 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 71
States / cities: Birmingham, Alabama • Irvine, California • Orange, California + 60 more

Conditions: Human Papilloma Virus
Interventions: Health Messaging via SMS, CDC Health Pamphlets; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Thymoma, Thymic Carcinoma
Interventions: PXD101with cisplatin+doxorubicin+cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Coronary Artery Disease
Interventions: Decision Aid, CAD Education; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 4
States / cities: San Francisco, California • Atlanta, Georgia • Kansas City, Missouri

Conditions: Neck Pain
Interventions: Augmented Exercise and Manual Therapy, General Exercise and Manual Therapy; Other
Lead sponsor: Des Moines University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Des Moines, Iowa • North Canton, Ohio • Youngstown, Ohio

Conditions: Health Behavior, Nutrition, Healthy, Activity, Motor
Interventions: Pro2col Health, Control; Behavioral
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Knee Osteoarthritis, Hip Osteoarthritis
Interventions: General Anesthesia, Spinal Anesthesia; Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 2,396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Endometrial Cancer
Interventions: carboplatin, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: CS5001, Rituximab, Gemcitabine, Oxaliplatin, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug · Biological
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: East Setauket, New York • New York, New York • Dallas, Texas

Conditions: Acute Lymphoblastic Leukemia
Interventions: prednisone, doxorubicin, vincristine, methotrexate, asparaginase, dexamethasone, cranial radiation, leucovorin, cytarabine, hydrocortisone, 6-mercaptopurine (6-MP), e. coli L-asparaginase; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Autism Spectrum Disorder
Interventions: AI Modules for Improving Social Communication; Device
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 35 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2050
U.S. locations: 1
States / cities: Stanford, California

Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Interventions: decitabine, NY-ESO-1 peptide vaccine, pegylated liposomal doxorubicin hydrochloride, sargramostim, incomplete Freund's adjuvant, immunohistochemistry staining method, liquid chromatography, mass spectrometry, reverse transcriptase-polymerase chain reaction, laboratory biomarker analysis, DNA methylation analysis, enzyme-linked immunosorbent assay; Drug · Biological · Other + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Cancer
Interventions: gemcitabine hydrochloride; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: New York, New York

Conditions: Insulin Sensitivity
Interventions: Ultrasound, OGTT with unlabeled glucose and liver NMR, OGTT with carbon-13 labeled glucose and liver NMR, CGM glucose reading, HEC - Hyperinsulinemic-Euglycemic-Clamp; Device · Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: Diabetes BOOST, Usual Care; Behavioral
Lead sponsor: Daniel Amante; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Richter Syndrome
Interventions: Obinutuzumab, Ibrutinib, CHOP; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Ovarian Cancer
Interventions: Liposomal Doxorubicin, Topotecan; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Adrenal Cortical
Interventions: Etoposide, Doxorubicin, Cisplatin, Streptozotocin, Mitotane; Drug
Lead sponsor: Collaborative Group for Adrenocortical Carcinoma Treatment; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA
Interventions: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 8
States / cities: Duarte, California • Basking Ridge, New Jersey • Commack, New York + 5 more

Conditions: Sepsis, Diagnosis, Emergencies
Interventions: Pediatric Sepsis Diagnostic Toolkit; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Month and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 955
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more

Search by objective public record fields.

Concussion Treatment in Older Adults

Effects of Motivating People With Schizophrenia to Exercise

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

Increasing Human Papillomavirus (HPV) Vaccine Uptake Via General Health Messaging

A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

Decisional Quality for Patients With Coronary Artery Disease

Manual Therapy and Augmented Exercise for Neck Pain

Effects of Pro2col Application on Health Outcomes

General vs Spinal in Total Joint Arthroplasty (TJA)

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

A Study in Adults With Untreated Acute Lymphoblastic Leukemia

Improving Social Communication in Individuals With ASD Using AI

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel

Mechanisms of Ultrasound Neuromodulation Effects in Diabetes

Development and Feasibility Testing of DM-BOOST Intervention.

Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer